DIPROSALIC ® Betamethasone + Salicylic acid

DIPROSALIC ® is a drug based on betamethasone dipropionate + salicylic acid

THERAPEUTIC GROUP: Corticosteroids other associations, dermatological preparations

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications DIPROSALIC ® Betamethasone + Salicylic acid

DIPROSALIC ® is indicated in the clinic in the treatment of local inflammatory diseases such as chronic eczema, neurodermatitis, psoriasis and seborrheic dermatitis.

Mechanism of action DIPROSALIC ® Betamethasone + Salicylic acid

DIPROSALIC ® owes its therapeutic action to the association of two important active ingredients, with different biological activities, and therefore effective in treating local inflammatory diseases.

More precisely :

Betamethasone is a corticosteroid capable, following topical application, of being distributed between the various layers of the epidermis, regulating the gene expression of these cells and thus reducing the production of inflammatory mediators, responsible for the typical inflammatory manifestations present in these circumstances;
Salicylic acid, applied topically, performs instead a sensitive keratolytic action, useful to restore the normal skin balance, evidently altered during seborrheic and hyperkeratotic affections, at the same time exerting an effective bacteriostatic action against both Gram positive and negative bacteria .

The aforementioned biological and therapeutic properties are also facilitated by good pharmacokinetic properties that greatly limit the systemic absorption of the active ingredients, thus reducing the risk of clinically relevant side effects.

Studies carried out and clinical efficacy

BETAMETASONE / SALICYLIC ACID IN THE TREATMENT OF PSORIASIS

Int J Pharm Investig. 2011 Jul; 1 (3): 139-47. doi: 10.4103 / 2230-973X.85963.

Study that evaluates the efficacy of Betamethasone diproprionate and salicylic acid microemulsions in the treatment of psoriasis, describing a good anti-inflammatory activity.

FISH OIL IN THE FORMULATION OF DRUGS BASED ON BETAMETASONE AND SALICYLIC ACID

Inflamm Res. 2010 Jan; 59 (1): 23-30. doi: 10.1007 / s00011-009-0065-z. Epub 2009 Jul 31.

Work that demonstrates how fish oil can facilitate the release of Betamethasone and salicylic acid, optimizing the therapeutic efficacy of topical medicines based on these active ingredients.

CALCIPOTRIOLO, BETAMETASONE AND SALICYLIC ACID IN THE TREATMENT OF THE PSORIASIS OF NAILS

Br J Dermatol. 1998 Oct; 139 (4): 655-9.

Work demonstrating that the addition of calcipotriol to Betamethasone and salicylic acid can further optimize the therapeutic efficacy of these active ingredients in the treatment of nail psoriasis.

Method of use and dosage

DIPROSALIC ®

Ointment with 0.064 grams of Betamethasone dipropionate and 3 gr of Salicylic acid per 100 grams of product.

Cutaneous solution of 0.064 gr of Betamethasone dipropionate and 2 gr of Salicylic acid per 100 grams of product.

The definition of the dosing schedule and the pharmaceutical format to be chosen is up to your doctor based on the general health of the patient and the severity of the relative clinical picture.

In principle, 1 or 2 daily applications are recommended, preferring the ointment in the treatment of chronic eczema, neurodermatitis and verrucous psoriasis, while the cutaneous solution in the treatment of psoriasis and dermatitis of scalp and hair covered areas.

Warnings DIPROSALIC ® Betamethasone + Salicylic acid

The correct use of DIPROSALIC ® evidently requires a previous medical examination in order to clarify the origin of the complained lesions and any prescriptive appropriateness.

The topical use of drugs such as cortisone drugs and salicylic acid also require compliance with other precautions to limit the incidence of side effects and to optimize the effectiveness of the therapy itself, such as avoiding the application of the drug for periods of particularly long time or on particularly extended skin regions, carefully cleanse the hands after each application and avoid the use of occlusive bandages.

The patient should also know that prolonged use of these drugs could lead to the emergence of adverse reactions that require suspension of therapy.

PREGNANCY AND BREASTFEEDING

The use of DIPROSALIC ® during pregnancy and in the subsequent period of breastfeeding is generally contraindicated due to the absence of studies able to better characterize the safety profile of the drug for the health of the fetus and infant.

Interactions

Drug interactions worthy of clinical note are not known at the moment, given the low systemic absorption that the active ingredients contained in DIPROSALIC ® face.

Contraindications DIPROSALIC ® Betamethasone + Salicylic acid

The use of DIPROSALIC ® is contraindicated in patients who are hypersensitive to the active ingredient or to one of its excipients and in patients suffering from serious bacterial and viral infections such as tuberculosis, lactic and viral processes.

Undesirable effects - Side effects

The use of DIPROSALIC ®, especially if prolonged over time, could expose the patient to the risk of local adverse reactions such as folliculitis, acne eruptions, hypetricosis, hypopigmentation, burning, contact dermatitis and skin atrophy.

Fortunately, the systemic side effects that are worthy of note are rarer.